REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

Roche Ethiopia: Build-up of an emerging market

Awasa College of Medicine23-01-2012. In a move to strengthen its foothold in East Africa, the Swiss pharma and diagnostics company is accelerating a major program to offer patients access to its products, educate health professionals, and recruit patients. A report by Bikila Wolde on Roche's plans and prospects.

 

 

Related Articles

The Global Dimension of EU Health and Food Policies

Paola Testori-Coggi, Director-General for Health and Consumers, European Commission

FAO: Major shifts expected in operations

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director on ensuring governance and compliance around the world - developing countries included.

Stem Cells: a discovery tool and a potential therapeutic modality

Prof. Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Jimmy Smith moves from World Bank to ILRI Kenya

Roche supports cancer care development program in Ethiopia

Corporate Press Release, 23-01-2012



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

2 pages; advert-free

Sigma Life Science and King's College London co-developing miRNA Target Identification Technology

05-05-2011. Sigma Life Science and King's College London announced an exclusive license to develop and commercialize new technology for the identification and validation of microRNA (miRNA) targets in research and clinical diagnostics. miRNAs function as critical regulators of gene expression in eukaryotic cells, with over 1,000 different miRNAs in the human genome already known to play multiple roles in gene regulation. Although the specific targets of most miRNAs are largely unknown, aberrant expression of miRNAs has been implicated in numerous disease states, making them important targets for clinical research in oncology, wound healing and infectious disease.
Currently, identification of miRNA targets is laborious and inefficient, relying on computer algorithms and subsequent validation by in vitro assays. To overcome this research bottleneck, scientists in the Division of Cancer Studies at King's have developed a technology allowing simple, accurate identification and validation of miRNA targets. Dr. Joop Gaken, lead researcher of this project, explained: "The role of miRNAs in cancer is well established, and several miRNAs clearly function as either oncogenes or tumor suppressor genes, although the target genes are unknown in the majority of cases. This new test is expected to enable the straightforward identification of target genes that are strongly regulated by a given miRNA, helping to elucidate important gene regulation events in vivo."
"miRNA research is a rapidly growing field, and this test is expected to be an invaluable asset to commercial and academic researchers working with miRNAs," commented Steven Suchyta, Market Segment Manager at Sigma-Aldrich. "We believe that the exclusive license agreement will allow Sigma Life Science and King's College London to work closely together to ensure rapid development of this technology for the benefit of the research community, and underlines our commitment to accelerating scientific discovery through innovative technology."

______________

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from  B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on  B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by  B2Bioworld.

QIAGEN Acquires Exclusive Licence for Key PI3K gene

Venlo, The Netherlands,February 08, 2010- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K gene could be a key biomarker for use as a companion diagnostic with certain cancer treatments. The studies suggest that mutations in the PI3K oncogene are predictive for the success of certain treatments of patients suffering from lung, breast, colorectal and other cancers. QIAGEN has an active PI3K assay development and partnering program with pharmaceutical companies to develop and market tests for new cancer drug candidates. Financial details were not disclosed.


QIAGEN already markets a PI3K test for research use. This test is based on real-time polymerase chain reaction (RT-PCR), a widely available technology to make DNA sequences visible through amplification. The assay, which uses technology that allows a very significant sensitivity, detects mutations frequently missed by sequencing methods.
The patent for PI3K mutations in human cancers was initially filed by researchers at Johns Hopkins who assessed the biomarker during their evaluation of tyrosine kinase inhibitors targeting the EGFR (Epidermal Growth Factor Receptor) pathway. Various EGFR inhibiting drugs have shown to be not effective in cancer patients with mutations in genes of the EGFR pathway (EGFR, K-RAS, B-RAF etc.). QIAGEN already markets several tests determining the mutation status in oncogenes. This portfolio includes tests for mutations of K-RAS and B-RAF, which are indicative for metastatic colorectal, lung and other cancers. The K-RAS test is CE-marked for companion diagnostic use with EGFR inhibitors Vectibix® and Erbitux® and is expected to be submitted for FDA approval shortly.


"This license agreement is another step forward for QIAGEN and for the use of novel therapeutics that rely on the widespread availability of the required PI3K companion diagnostic test", said Peer M. Schatz, CEO of QIAGEN. "We are looking forward to developing drug-diagnostic combinations together with pharmaceutical partners for the selection of the right patient for the right medicine. This concept allows cancer patients to receive better treatments and can support healthcare systems to provide the most useful therapies in cost effective ways."


QIAGEN is active in more than 15 partnerships with pharmaceutical and large biotech companies in the field of personalized healthcare, including AstraZeneca, Merck, Amgen, Lilly, Boehringer-Ingelheim and Pfizer. QIAGEN has developed and markets approximately 20 companion diagnostics assays in personalized healthcare and has a strong pipeline targeting to further expand this leading franchise.

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.

Clear away complete confusion of terms - The case of stem cell research

Dr Bernhard Kirschbaum (C) Wolf G Kroner 2009 February 2009. While many ethical questions surrounding the use of stem cells have been satisfactorily answered, a number of unresolved methodological and technical issues hamper applications in the pharmacceutical industry. Where are the stumbling blocks of today? What is Merck’s and Merck Serono’s approach, and with what prospects?

 

 

Related Articles

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

The Myriad Way

Peter D Meldrum, CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Stem Cells - Failings and Deliveries

Towards Pharma Standards for Assays: Drug Testing with Embryonic Stem Cells

 

 

or access the complete Stem Cell Insights Collection



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 2 pages

Top 10 Tags

All Tags (2094)